NGM · Medical - Diagnostics & Research

Biodesix, Inc. (BDSX) Stock

$25.63 -2.99% NGM: BDSX Healthcare

Valuation

MetricValue
Price$25.63
Market Cap$208.64M
P/E Ratio-8.74
P/B Ratio31.21
P/S Ratio2.19
EPS (TTM)$-4.67
52-Week High$31.97
52-Week Low$5.26
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-788.19%
ROA-29.12%
ROCE-25.73%
Gross Margin81.11%
Operating Margin-6.84%
Net Margin-26.97%
Debt/Equity7.85
Current Ratio1.87

Annual Financials (USD)

Metric20212022202320242025
Revenue$55.0M$38.0M$49.0M$71.0M$88.0M
Operating Profit$-41.0M$-51.0M$-41.0M$-34.0M$-28.0M
Net Profit$-43.0M$-65.0M$-52.0M$-43.0M$-35.0M
EPS$-31.54$-31.09$-12.70$-6.62$-4.67
Op Margin-75.1%-132.4%-84.2%-48.4%-31.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$76.0M$93.0M$99.0M$97.0M$87.0M
Total Liabilities$56.0M$72.0M$95.0M$76.0M$90.0M
Cash$33.0M$43.0M$26.0M$26.0M$19.0M
Borrowings$10.0M$32.0M$61.0M$62.0M$73.0M

Latest News

Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026 GlobeNewswire · Jul 22, 2026 Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year? Zacks · Jul 1, 2026 Biodesix (BDSX) Stock Gets Fair Value Bump As Analysts Back Growth Path Simply Wall St. · Jun 26, 2026 Roth Capital Initiates Biodesix at Buy With $32 Price Target MT Newswires · Jun 25, 2026 Biodesix (BDSX) Surges 10.5%: Is This an Indication of Further Gains? Zacks · Jun 19, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-28.0M$-45.0M$-23.0M$-49.0M$-23.0M
Investing Cash Flow$-5.0M$-7.0M$-46.0M$-7.0M$-1.0M
Financing Cash Flow$0$-17.0M$-9.0M$-4.0M$-1.0M
Net Cash Flow$-30.0M$10.0M$-17.0M$0$-7.0M
Free Cash Flow$-31.0M$-49.0M$-46.0M$-52.0M$-24.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.14
EV / EBITDA-18.73
FCF Yield-9.04%
Quick Ratio2.85
Interest Coverage-2.54
Return 1Y237.54%
Return 3Y-4.82%
Return 5Y-90.92%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALGSAligos Therapeutics, Inc. $5.31 -0.19% -0.76 $32.86M 0.00%
INMBINmune Bio Inc. $1.83 -1.61% -2.81 $48.65M 0.00%
MRSNMersana Therapeutics, Inc. $29.08 +0.00% -2.59 $145.36M 0.00%
NOTV $0.27 +0.00% -0.14 $9.42M 0.00%
OKUROnKure Therapeutics, Inc. $2.30 -2.13% -0.73 $93.14M 0.00%

About Biodesix, Inc.

Biodesix, Inc. is led by CEO Scott Hutton, employs 273 people, headquartered in US, publicly traded since 2020.

Biodesix, Inc. (BDSX) stock trades at $25.63 with a market capitalization of $208.64M. The stock is valued at a price-to-earnings (P/E) ratio of -8.74, price-to-book of 31.21, price-to-sales of 2.19. Over the past 52 weeks the stock has ranged between $5.26 and $31.97, and currently trades 19.8% below its 52-week high.

On profitability, Biodesix, Inc. generates a return on equity (ROE) of -788.19%, return on capital employed of -25.73%, an operating margin of -6.84%, a net profit margin of -26.97%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1162.55 -0.60% JNJ Johnson & Johnson $255.86 -0.24% ABBV AbbVie Inc. $273.26 +0.31% MRK Merck & Company, Inc. Common Stock (new) $141.89 -0.34% UNH UnitedHealth Group Incorporated Common Stock (DE) $384.13 +3.55% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $656.66 +0.72% AMGN Amgen Inc. $406.05 -0.34% GILD Gilead Sciences, Inc. $147.20 +0.07% ABT Abbott Laboratories $98.92 +0.44% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides